Novartis inks licensing deal worth up to $1.8B for oral peptide drugs
Source: SeekingAlpha
2026-02-18 09:21:20 ET
More on Novartis
- Novartis: Value Price, Growth Pipeline
- Novartis AG 2025 Q4 - Results - Earnings Call Presentation
- Novartis AG (NVS) Q4 2025 Earnings Call Transcript
- Novartis breaks ground on new R&D center in San Diego
- Novartis reports mixed Q4 results; initiates FY26 soft outlook
Read the full article on Seeking Alpha
For further details see:
Novartis inks licensing deal worth up to $1.8B for oral peptide drugs
Novartis AG
NASDAQ: NVS
NVS Trading
-0.26% G/L:
$150.47 Last:
852,043 Volume:
$151.84 Open:
NVS Latest News
February 24, 2026 04:52:00 pm
Could Novartis Stock Quietly Help You Build a Millionaire Retirement Portfolio?
NVS Stock Data
$303,205,301,793
1,889,070,162
N/A
868
N/A
Pharmaceuticals
Healthcare
CH
Basel
